Cancers & treatments·Regimen libraryFirst line

Gemcitabine monotherapy

Checked 2026-09-09

Frail patients or adjuvant when combinations are not tolerated

One cycle

every 28 days × 6 · about 24 weeks in total

28-day cycle × 6 (adjuvant); until progression (about 24 weeks)Intravenous

Components

Drug	Dose	Route	Days	Note
Gemcitabine Nucleoside analogue (deoxycytidine)	1,000 mg/m²	IV	D1, 8, 15

Cycles

6 (adjuvant); until progression

28-day cycle

Emetogenicity

Low (10-30%)

G-CSF

Not routine

Used in

Pancreatic ductal adenocarcinoma Biliary tract cancer (cholangiocarcinoma)

Products

Gemcitabine

Source

Burris, JCO 1997 (7 weekly doses then 3 of 4 weeks); CONKO-001 adjuvant

Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.